After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
Stocks Info
Denali Therapeutics Inc is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Denali Therapeutics Inc is $2.78B. A total of 1.85 million shares were traded on the day, compared to an average of 1.87M shares.
In the most recent transaction, Schuth Alexander O. sold 2,937 shares of DNLI for 13.58 per share on Aug 12 ’25. After the transaction, the COFO and Secretary now owns 242,346 company shares. In a previous transaction on Aug 12 ’25, Ho Carole sold 2,937 shares at 13.58 per share. DNLI shares that Chief Medical Officer owns now total 217,391.
Among the insiders who sold shares, Ho Carole disposed of 806 shares on Aug 13 ’25 at a per-share price of $14.64. This resulted in the Chief Medical Officer holding 216,585 shares of DNLI after the transaction. In another insider transaction, CAROLE HO bought 806 shares at $13.22 per share on Aug 13 ’25.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, DNLI has a high of $26.18 and a low of $10.57.
As of this writing, DNLI has an earnings estimate of -$0.76 per share for the current quarter. EPS was calculated based on a consensus of 14.0 estimates, with a high estimate of -$0.62 per share and a lower estimate of -$0.93. The company reported an EPS of -$0.67 in the last quarter
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. DNLI’s latest balance sheet shows that the firm has $865.41M in Cash & Short Term Investments as of fiscal 2021. There were $64.01M in debt and $378.25M in liabilities at the time. Its Book Value Per Share was $6.32, while its Total Shareholder’s Equity was $962.29M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DNLI is Buy with a score of 4.89.
